NUMD Nu-Med Plus, Inc.
Gold and Silver Ores · OTC · SEC CIK 1543637 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY—
TTM net income YoY17.8%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-650.1%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets3,529.1%
Debt / equity—
Current ratio0.03x
Interest coverage-6.77x
Cash quality & payout
Operating cash flow / net income0.85x
Accruals ratio-94.9%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| SG&A expense | $23,115 | $34,324 |
| Operating income | -$48,955 | -$63,331 |
| Interest expense | $7,227 | $5,014 |
| Pretax income | -$56,182 | -$68,345 |
| Net income | -$56,182 | -$68,345 |
| EBITDA | -$48,955 | -$63,331 |
| EPS (basic) | 0.00 | 0.00 |
| EPS (diluted) | 0.00 | 0.00 |
| Weighted avg. shares (diluted) | 83.55M | 83.55M |
| Balance sheet | ||
| Cash & equivalents | $661 | $2,373 |
| Current assets | $7,911 | $9,373 |
| PP&E, net | $0 | — |
| Total assets | $7,911 | $9,373 |
| Current liabilities | $279,189 | $224,469 |
| Long-term debt | $0 | — |
| Total debt | $0 | — |
| Total liabilities | $279,189 | $224,469 |
| Shareholders' equity | -$271,278 | -$215,096 |
| Net debt | -$661 | — |
| Shares outstanding | 83.55M | 83.55M |
| Cash flow statement | ||
| Operating cash flow | -$47,979 | -$4,433 |
| Financing cash flow | $46,267 | — |
| Depreciation & amortization | $0 | $0 |
Free plan shows the latest 2 periods; Pro shows all 14 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.